Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/7238
Title: Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial.
Authors: Mourão, Aline de Oliveira Magalhães
Ferreira, Wandiclécia Rodrigues
Martins, Maria Auxiliadora Parreiras
Reis, Adriano Max Moreira
Carrilo, Maria Ruth Gaede Gonçalves
Guimarães, Andrea Grabe
Ev, Lisiane da Silveira
Keywords: Diabetes mellitus
Pharmacists
Issue Date: 2012
Citation: MOURÃO, A. de O. M. et al. Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial. International Journal of Clinical Pharmacy, v. 35, p.79-86, 2012. Disponível em: <http://link.springer.com/article/10.1007/s11096-012-9710-7>. Acesso em: 10 out. 2016.
Abstract: Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trialwas conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels C7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.
URI: http://www.repositorio.ufop.br/handle/123456789/7238
metadata.dc.identifier.uri2: http://link.springer.com/article/10.1007/s11096-012-9710-7
metadata.dc.identifier.doi: https://doi.org/10.1007/s11096-012-9710-7
ISSN: 2210-7711
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_PharmaceuticalCareProgram.pdf
  Restricted Access
230,43 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.